Macular Degeneration
An Introduction to Macular Degeneration
The treatment landscape for macular degeneration is evolving with many new potential therapies under investigation. The standard of care in wet age-related macular degeneration (AMD) was revolutionised in 2005 with the introduction of anti-VEGF therapies, and current research into port delivery systems and drug combinations aim to provide longer-lasting treatments. Dry AMD is a challenging condition with no current treatment option, but research into stem cell therapies and drugs that slow the progression of geographic atrophy show much promise.
Browse the content below, to see leading experts discuss the latest data in video interviews and short articles from our conference hub. You can also view the selection of peer-reviewed articles from our journals. If you’re looking to learn more about the impact of these developments on patient outcomes, our educational activities are a great resource.
Our supporting partners do not constitute an endorsement of the content on this page.
The FDA has accepted Outlook Therapeutics’ resubmitted biologics license application for bevacizumab-vikg (LYTENAVA™; Outlook Therapeutics, Inc., Iselin, NJ, USA) for the treatment of neovascular, or wet, age-related macular degeneration (AMD). The application has been classified as a Class 1 review, with a Prescription Drug User Fee Act target action date of July 29, 2026.1
The 40th World Ophthalmology Congress (WOC2026) will take place at the Prague Congress Centre, Czech Republic, from June 26–29, 2026, bringing together ophthalmologists and eye care professionals from across the world
This week in ophthalmology: new phase 2/3 data in metastatic uveal melanoma, clinically relevant updates from the European Glaucoma Society (EGS) Congress, phase 3 results for a topical diabetic macular edema (DME) candidate, a bevacizumab resubmission for neovascular age-related macular degeneration (AMD), and a link between dermatitis and retinal detachment risk. Here are five stories to catch up on this week.
New data presented at the ARVO 2026 Annual Meeting highlighted how the treatment landscape for neovascular age-related macular degeneration (nAMD) continues to evolve beyond conventional anti-VEGF therapy. Across gene therapy, sustained-release drug delivery platforms and next-generation anti-VEGF strategies, investigators focused on a common challenge: how to maintain long-term visual and anatomical outcomes while reducing the burden of frequent intravitreal injections.
A session at the ARVO Annual Meeting 2026 explored the evolving role of AI in Age-related Macular Degeneration clinical trials, highlighting both the transformative potential of automated imaging analysis and the practical barriers that continue to limit broader implementation. Central to this discussion was the CLEAR study, an initiative led through the International Retinal Imaging Society that aims to establish a standardized validation framework for AI tools used in clinical-trial decision-making. In this Q&A, Dr Omer Trivizki (Bascom Palmer Eye Institute and Tel Aviv Medical Center) discusses how these same principles of standardization, transparency and clinically meaningful interpretation extend beyond imaging algorithms to emerging large language models. Drawing on his work at the Israeli GA Research Center and through CLEAR, he reflects on the risks of incomplete yet highly convincing AI-generated patient advice, particularly in rare inherited retinal diseases, and why clinical judgment, critical thinking and human connection must remain at the center of patient education and trial decision-making.
Designed for busy clinicians, these short, focused articles cut through theory to highlight what truly matters at the point of care including what works, what to watch for, and how to optimise outcomes in real-world settings.
The first months of 2026 have already seen a number of interesting studies and reviews published across the ophthalmology literature, setting the stage for another year of progress in the field. Below, we highlight a selection of recent papers from major journals that we found particularly notable over the past few weeks.
As 2026 gets underway, January has delivered a busy start across regulation, clinical research and community awareness. Here are some of the top news and research stories from the month.
In this expert pearl, Dr Alessandro Arrigo draws on personal experience to share practical insights into individualising anti-VEGF treatment in routine clinical practice.
Initial results from the Phase 1 GARDian1 trial of OCU410ST, recently published in Eye, report early safety and exploratory efficacy findings in adults with Stargardt disease (STGD1).
2025 has brought a wave of innovation and developments that are already reshaping day-to-day clinical practice. We asked our key faculty to reflect on what they believe has been most impactful so far this year – here’s what they told us.
As 2025 draws to a close, we’re celebrating another remarkable year of growth, collaboration and innovation at touchOPHTHALMOLOGY. From thought-provoking expert interviews and peer-reviewed research, to dynamic conference coverage and an expanding portfolio of medical education, this year has been ...
Specializing in ophthalmology is an exciting milestone – but it can also feel overwhelming. The transition from training to independent practice comes with big decisions, new responsibilities and the pressure to build a career that will stand the test of time. We asked members of our faculty and Future Leaders what guidance they would offer to colleagues just beginning their careers.
In this Q&A, we speak with distinguished vitreoretinal surgeon Dr Dhanashree Ratra, who shares her perspectives on the most pressing challenges in retina care, the advances transforming her daily practice, and the rapidly expanding role of artificial intelligence in the field.
In this episode, Nicky speaks with Prof. Georgina Ellison-Hughes from King’s College London about the groundbreaking field of senolytics and their potential to advance the treatment of age-related diseases. From understanding the science behind cellular senescence to how senolytic drugs work and what early clinical trials reveal, this episode explores an exciting frontier in longevity medicine.
In this episode of Visionary Voices, we welcome Associate Professor Grace Vincent from CQUniversity’s Appleton Institute. A leading expert on sleep and shift work, Grace explores how disrupted sleep affects physician health in both the short and long term, as well as its impact on safety and performance. We also discuss what this means for patient outcomes and share practical strategies to manage sleep loss.
At EURETINA 2025 in Paris, Dr David Eichenbaum presented late-breaking data on the use of structural biomarkers to predict exudative AMD in geographic atrophy (GA). Using real-world datasets and AI-powered analysis via the EvidenceEngine platform, his research demonstrates how multimodal imaging and validated biomarkers can deliver rapid, scalable insights into disease progression. In this Q&A, Dr Eichenbaum shares his perspectives on: How AI-based approaches compare with traditional clinical trial methods The key biomarkers linked to increased exudation risk in GA The potential for AI-driven biomarker research to transform retinal disease management and future clinical research
Log into your Touch Account
Keep track of your clinical interests and newsletter subscriptions.
Sign up with an Email
Or use a .
Register now for FREE access
Already registered? Login below.
